| Code | CSB-RA011664MB10HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Ziltivekimab, targeting interleukin-6 (IL-6), a pleiotropic pro-inflammatory cytokine that plays a central role in immune regulation and inflammatory responses. IL-6 mediates its effects through both classical and trans-signaling pathways, influencing acute phase responses, hematopoiesis, and metabolic processes. Dysregulated IL-6 signaling is implicated in numerous pathological conditions, including chronic inflammatory diseases, autoimmune disorders, cardiovascular disease, and certain malignancies. Elevated IL-6 levels are associated with systemic inflammation and serve as a biomarker for disease activity in various inflammatory conditions.
Ziltivekimab is a therapeutic antibody designed to neutralize IL-6, currently under clinical investigation for cardiovascular and inflammatory conditions. This biosimilar provides researchers with a valuable tool for investigating IL-6-mediated pathways, studying inflammatory mechanisms, evaluating therapeutic interventions, and exploring the role of IL-6 in disease pathogenesis. It enables in vitro and in vivo studies examining cytokine biology, immune cell function, and inflammation-related processes across diverse research applications.
There are currently no reviews for this product.